Drug Overview
Nexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine kinase 3, vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, and platelet-derived growth factor receptor. As a result of its multi-targeted nature, it is thought to inhibit both angiogenesis and proliferation of tumor cells.
Nexavar was the first systemic therapy approved for the first-line treatment of advanced hepatocellular carcinoma.
Gaining approval in the US in 2007, Nexavar has been firmly established as the standard of care in this patient group, facing no competition in this setting until the approval of Lenvima (lenvatinib; Eisai/Merck & Co) in 2017 (US). Nexavar is nearing the end of its product lifecycle, with generic competition expected in 2020 (US), 2021 (EU), and 2022 (Japan).
Nexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine kinase 3, vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, and platelet-derived growth factor receptor. As a result of its multi-targeted nature, it is thought to inhibit both angiogenesis and proliferation of tumor cells.
Nexavar was the first systemic therapy approved for the first-line treatment of advanced hepatocellular carcinoma.
Gaining approval in the US in 2007, Nexavar has been firmly established as the standard of care in this patient group, facing no competition in this setting until the approval of Lenvima (lenvatinib; Eisai/Merck & Co) in 2017 (US). Nexavar is nearing the end of its product lifecycle, with generic competition expected in 2020 (US), 2021 (EU), and 2022 (Japan).
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
